These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 7705494)

  • 21. Measles, mumps, and rubella--vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Watson JC; Hadler SC; Dykewicz CA; Reef S; Phillips L
    MMWR Recomm Rep; 1998 May; 47(RR-8):1-57. PubMed ID: 9639369
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Seroconversion rates to combined measles-mumps-rubella-varicella vaccine of children with upper respiratory tract infection.
    Dennehy PH; Saracen CL; Peter G
    Pediatrics; 1994 Oct; 94(4 Pt 1):514-6. PubMed ID: 7936862
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Humoral and cellular immune response after measles vaccination in Taiwan.
    Huang CL; Yang YH; Wang LC; Lin YT; Tsai YY; Chiang BL
    J Microbiol Immunol Infect; 2005 Jun; 38(3):169-75. PubMed ID: 15986066
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Progress in measles and rubella elimination in Iran.
    Esteghamati A; Gouya MM; Zahraei SM; Dadras MN; Rashidi A; Mahoney F
    Pediatr Infect Dis J; 2007 Dec; 26(12):1137-41. PubMed ID: 18043452
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Experience with preventive measles, mumps and rubella vaccination in unified Germany].
    Gerike E; Tischer A
    Gesundheitswesen; 1993 Jan; 55(1):38-9. PubMed ID: 8435543
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Measles--United States, 1996, and the interruption of indigenous transmission.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 1997 Mar; 46(11):242-6. PubMed ID: 9082179
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interpretation of serological surveillance data for measles using mathematical models: implications for vaccine strategy.
    Gay NJ; Hesketh LM; Morgan-Capner P; Miller E
    Epidemiol Infect; 1995 Aug; 115(1):139-56. PubMed ID: 7641827
    [TBL] [Abstract][Full Text] [Related]  

  • 28. From the Centers for Disease Control and Prevention. Measles--United States, 1996, and the interruption of indigenous transmission.
    JAMA; 1997 May; 277(17):1345-6. PubMed ID: 9134928
    [No Abstract]   [Full Text] [Related]  

  • 29. [Morbidity, vaccine coverage and immunity against measles, mumps and rubella in a Gallician population from 2 to 5 years old].
    Vázquez Fernández E; López Rois F; Vázquez Carrete JA; Gómez Tato B; Alvarez Ares M
    An Esp Pediatr; 1987 Jul; 27(1):27-31. PubMed ID: 3662251
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A 24-year review on the epidemiology and control of measles in Singapore, 1981-2004.
    Ong G; Hoon HB; Ong A; Chua LT; Kai CS; Tai GK
    Southeast Asian J Trop Med Public Health; 2006 Jan; 37(1):96-101. PubMed ID: 16771219
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Uptake of measles containing vaccines in the measles, mumps, and rubella second dose catch-up programme in Wales.
    Thomas DR; King J; Evans MR; Salmon RL
    Commun Dis Public Health; 1998 Mar; 1(1):44-7. PubMed ID: 9718839
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The contribution of single antigen measles, mumps and rubella vaccines to immunity to these infections in England and Wales.
    Sonnenberg P; Crowcroft NS; White JM; Ramsay ME
    Arch Dis Child; 2007 Sep; 92(9):786-9. PubMed ID: 17412744
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Measles, mumps and rubella: vaccination rate and seroprevalence in 8th grade students of 8 different sites in Switzerland 1995/96].
    Stohrer-Draxl P; Amstad H; Grize L; Gassner M; Takken-Sahli K; Bourquin C; Braun-Fahrländer C
    Praxis (Bern 1994); 1999 Jun; 88(24):1069-77. PubMed ID: 10420798
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Children who miss immunisation: implications for eliminating measles.
    Evans MR
    BMJ; 1995 May; 310(6991):1367-8. PubMed ID: 7787540
    [No Abstract]   [Full Text] [Related]  

  • 35. Efficacy and safety of vaccination of marrow transplant recipients with a live attenuated measles, mumps, and rubella vaccine.
    Ljungman P; Fridell E; Lönnqvist B; Bolme P; Böttiger M; Gahrton G; Linde A; Ringdén O; Wahren B
    J Infect Dis; 1989 Apr; 159(4):610-5. PubMed ID: 2647859
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Preventive care for children: immunization in England and Wales.
    Goodwin S
    Pediatrics; 1990 Dec; 86(6 Pt 2):1056-60. PubMed ID: 2243739
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ongoing measles and rubella transmission in Georgia, 2004-05: implications for the national and regional elimination efforts.
    Doshi S; Khetsuriani N; Zakhashvili K; Baidoshvili L; Imnadze P; Uzicanin A
    Int J Epidemiol; 2009 Feb; 38(1):182-91. PubMed ID: 19074954
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Certain problems with limits of immunity against measles, mumps and rubella].
    Magdzik W
    Przegl Epidemiol; 1993; 47(1-2):47-53. PubMed ID: 8351387
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The virtual elimination of rubella and mumps from the United States and the use of combined measles, mumps and rubella vaccines (MMR) to eliminate measles.
    Bart KJ; Orenstein WA; Hinman AR
    Dev Biol Stand; 1986; 65():45-52. PubMed ID: 3104117
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Increase of vaccination coverage by mass media and individual approach: intensified measles, mumps, and rubella prevention program in Finland.
    Paunio M; Virtanen M; Peltola H; Cantell K; Paunio P; Valle M; Karanko V; Heinonen OP
    Am J Epidemiol; 1991 Jun; 133(11):1152-60. PubMed ID: 2035518
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.